CN Patent

CN104473911A — 包含阿地尼亚的用于治疗哮喘和慢性阻碍性肺病的吸入式组合物

Assigned to Almirall SA · Expires 2015-04-01 · 11y expired

What this patent protects

一种供吸入的药剂组成物，包括干粉型态的阿地尼亚(aclidinium)在药理学上可接受的盐，并与一药理学上可接受的干粉载体相混合，且提供有相当于约400微克阿地溴铵(aclidinium bromide)的阿地尼亚定量标称剂量。

USPTO Abstract

一种供吸入的药剂组成物，包括干粉型态的阿地尼亚(aclidinium)在药理学上可接受的盐，并与一药理学上可接受的干粉载体相混合，且提供有相当于约400微克阿地溴铵(aclidinium bromide)的阿地尼亚定量标称剂量。

Drugs covered by this patent

Tudorza Pressair (ACLIDINIUM BROMIDE) · Covis

Patent Metadata

Patent number: CN104473911A
Jurisdiction: CN
Classification: —
Expires: 2015-04-01
Drug substance claim: No
Drug product claim: No
Assignee: Almirall SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.